Saturday, January 30, 2021 1:35:12 PM
I'm in it for the COVID. I have no faith that the psychedlics side will ever amount to much. Not in the short-term. Maybe if Joe signs a few exec orders that put a flame under them. Otherwise, it's Bucillamine and COVID that will drive this PPS over the next 1-3 months. If FDA trial results are bad, we will see a massive sell-off IMO. If they are good, we'll be $1++
Recent RVVTF News
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
